Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$235.11 USD
-2.72 (-1.14%)
Updated Jul 22, 2024 11:54 AM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ALNY 235.11 -2.72(-1.14%)
Will ALNY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALNY
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Jun 25, 2024
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Other News for ALNY
Healthcare 2024 Second Half Outlook
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam StockĀ Is a Blockbuster Biopharma In the Making
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis